Last reviewed · How we verify
EMLA CREAM 5 mg
At a glance
| Generic name | EMLA CREAM 5 mg |
|---|---|
| Also known as | EMLA CREAM, PRILOCAIN 25 LIDOCAIN 25 |
| Sponsor | Ain Shams Maternity Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Transdermal Microneedle Lignocaine Delivery Versus EMLA Patch for Topical Analgesia Before Venepuncture Procedure To Adults in Clinical Setting (PHASE1, PHASE2)
- A Comparative Study of Selective Dorsal Neurectomy, Pulsed Radiofrequency Neuromodulation, and Intragranular Hyaluronic Acid Injection for Premature Ejaculation (NA)
- Efficacy of the Use of Cellular Matrix/ A-CP-HA Kit (PHASE4)
- Simultaneous Versus Sequential Fractional CO2 Laser and Subcision Combination for Post-acne Atrophic Scars: A Split-face Comparative Study. (NA)
- Fractional CO2 Laser Fenestration and Steroid Delivery in HS Lesions (EARLY_PHASE1)
- Efficacy of Transdermal Microneedle Patch for Topical Anesthesia Enhancement in Paediatric Thalassemia Patients (PHASE2)
- Evaluation of the Effect Induced by Repeated Administration of Topical Local Anaesthetic (EMLA) on Itch (NA)
- A Mechanistic Evaluation of the Nociceptive Desensitizing Properties of Topical Capsaicin (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EMLA CREAM 5 mg CI brief — competitive landscape report
- EMLA CREAM 5 mg updates RSS · CI watch RSS
- Ain Shams Maternity Hospital portfolio CI